A
Class-leading
Injectable division · GLP-1/GIP dual
Tirzepatide
Eli Lilly · Zepbound · once weekly
Approved
Division standing
#2 of 5
Injectable division
← Tolerability cost (bands)% body weight lost →
Mild018% vs placebo
Tolerability: the cost
Mild6.2% vs 2.6% placebo
AE-discontinuation +3.6 points, at the 15 mg weekly. From SURMOUNT-1.
Efficacy
18%15 mg · placebo-adjusted · 72 wk
SURMOUNT-1: 20.9% vs 3.1% placebo, an 18-point gap on the treatment-regimen estimand.
The uncommon drug that leads on the scale and stays easy to tolerate.
Convenience profile: you weigh it, not us
Route
Subcutaneous injection
Frequency
Once weekly
Food / water rule
None
Titration
Four-step escalation over about 20 weeks
Storage
Refrigerated (room temperature up to 21 days)
Provenance: every number traces back
TrialSURMOUNT-1 · NCT04184622
Estimandtreatment-regimen estimand
Populationnon-diabetic obesity
Dose15 mg weekly
SourceJastreboff NEJM 2022
Verdict confirmed5 Jul 2026